Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Drugs In Development, 2023’, provides an overview of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)
- The report reviews pipeline therapeutics for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) therapeutics and enlists all their major and minor projects
- The report assesses Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
A. Menarini Industrie Farmaceutiche Riunite SrlAbbVie Inc
Actinium Pharmaceuticals Inc
Al-Azhar University
AOP Health
Arromax Pharmatech Co Ltd
Ascentage Pharma Group International
Astex Pharmaceuticals Inc
Autolus Therapeutics Plc
Bio-Path Holdings Inc
Brillian Pharma Inc.
Bristol-Myers Squibb Co
Celularity Inc
Central Drug Research Institute
Charite University Hospital of Berlin
Chimeric Therapeutics Ltd
Coeptis Therapeutics Holdings Inc
Curis Inc
Enliven Therapeutics Inc
Escend Pharmaceuticals Inc
ExCellThera Inc
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
Fusion Pharmaceuticals US Inc
Gamida Cell Ltd
Gifu University
GT Biopharma Inc
Handa Pharmaceuticals LLC
HEC Pharma Co Ltd
Helocyte Biosciences Inc
Henan Provincial People's Hospital
HighPass Bio Inc
Housey Pharmaceutical Research Laboratories LLC
iCell Gene Therapeutics LLC
Ilyang Pharmaceutical Co Ltd
ImmunoForge Co Ltd
IN8bio Inc
Inhibikase Therapeutics Inc
InnoCure Therapeutics Inc
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Kartos Therapeutics Inc
Kiadis Pharma NV
Kura Oncology Inc
Lin Bioscience Inc
Lotus Pharmaceutical Co Ltd
MAA Laboratories Inc
MacroGenics Inc
Mana Therapeutics Inc
MedPacto Inc
Medytox Inc
Millennium Pharmaceuticals Inc
Nanjing Sanhome Pharmaceutical Co Ltd
Nanocopoeia LLC
Novartis AG
Novelty Nobility Inc
Oncologia no Hospital de Clinicas de Porto Alegre
Orca Biosystems Inc
Otsuka Pharmaceutical Co Ltd
Pfizer Inc
Pharma Mar SA
PharmaEssentia Corp
Prescient Therapeutics Ltd
PRISM Pharma Co.
Ltd.
PYC Therapeutics Ltd
Radboud University
Samsung Medical Center
Sanofi
ShanghaiTech University
Shenogen Pharma Group Ltd
Shenzhen Targetrx Inc
Shorla Oncology
Stanford University
Sun Pharma Advanced Research Company Ltd
Synactix Pharmaceuticals Inc
Takeda Pharmaceutical Co Ltd
Terns Pharmaceuticals Inc
The First Affiliated Hospital of the University of Science and Technology of China
Theseus Pharmaceuticals Inc
Tohoku University
TotalClarity Inc
University Medical Center Utrecht
University of California San Diego
University of Chicago
University of Haifa
University of Palermo
University of Science and Technology of China
University of Texas MD Anderson Cancer Center
Vincerx Pharma Inc
Xencor Inc
Xspray Pharma AB